460086-95-7

Usage

Uses

Used in Synthetic Organic Chemistry:
1-(7-BROMOBENZOFURAN-2-YL)ETHANONE is used as a synthetic intermediate for the preparation of various organic compounds. Its bromine atom and ketone functional group make it a versatile building block in organic synthesis, facilitating the creation of a wide range of chemical products.
Used in Pharmaceutical Industry:
1-(7-BROMOBENZOFURAN-2-YL)ETHANONE is used as a pharmaceutical precursor for the development of new drugs. Its unique structure and reactivity can be exploited to design and synthesize bioactive molecules with potential therapeutic applications.
Used in Materials Science:
1-(7-BROMOBENZOFURAN-2-YL)ETHANONE is used as a component in the development of new materials. Its chemical properties may contribute to the creation of advanced materials with specific characteristics for use in various industries, such as electronics, coatings, or polymers.

Upstream product

• 1829-34-1 2-hydroxy-3-bromobenzaldehyde 
• 78-95-5 chloroacetone 
• 598-31-2 1-bromoacetone 

Downstream Products

• 460086-96-8 2-Acetyl-7-(2-propoxy-3-tert-butyl-5-ethylphenyl) benzo[b]furan 

Relevant academic research and scientific papers

Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study

Signal transducer and activator of transcription 3 (STAT3) is identified as a promising target for multiple cancer therapy and attracts widespread concern. Herein, we reported the discovery of a series of 2-acetyl-7-phenylamino benzofuran derivatives as STAT3 inhibitors using scaffold fusion strategy. Further structure activity relationship study led to the discovery of compound C6, which displayed the most potent anti-proliferation activities against MDA-MB-468 cells (IC50 = 0.16 μM). Western blot assay demonstrated that C6 inhibited the activation of STAT3 (Tyr705) without influencing the phosphorylation of STAT1 (Tyr701). Further mechanistic studies indicated that C6 caused a notable G2/M cycle-arresting and early apoptosis in a concentration-dependent manner in MDA-MB-468 cells. Finally, molecular modelling study elucidated the binding mode of C6 in STAT3 SH2 domain.

1,3-disubstituted ketene compound and application thereof

The invention relates to a 1,3-disubstituted ketene compound with a structure as shown in a formula (I) and application thereof. The compound mainly activates a PPAR (Peroxisome Proliferators-Activated Receptor) alpha, and also has excitation activity for PPPA delta and PPPA gamma. The 1,3-disubstituted ketene compound can be used for treating various diseases related to the PPAR regulation abnormality, such as NASH (nonalcoholic steatohepatitis), and particularly treating nonalcoholic hepatitis, also has potentials for treating diabetes, obesity, fibrotic diseases, cardiovascular diseases (comprising a heart failure, atherosclerosis and the like), kidney diseases (comprising chronic nephrosis, a kidney failure and the like), brain degenerative diseases (comprising the alzheimer disease and the like) and the like, and has higher application value. The formula is shown in the description.

NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.

Retinoid x receptor modulators

The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.